StockNews.AI
IMRX
StockNews.AI
2 hrs

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

1. IMRX will host a conference call on September 29, 2025. 2. Updated survival and safety data for atebimetinib will be discussed. 3. The data involves first-line pancreatic cancer patients with 9 months follow-up. 4. Key results will be presented at the PanCAN Scientific Summit 2025. 5. Atebimetinib is in Phase 2a trial for advanced solid tumors.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive data presentation and survival outcomes for atebimetinib can significantly boost IMRX's investor confidence. Historical trends show that successful trial results often lead to share price increases.

How important is it?

The article emphasizes significant upcoming data disclosure, which could affect stock performance directly. High investor interest in cancer therapies enhances importance.

Why Short Term?

The immediate impact is driven by upcoming conference call and dissemination of results, likely influencing short-term investor sentiment. However, proof of long-term efficacy and approval would be needed for sustained impact.

Related Companies

GILDAMGNMRNAREGNBMY
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. “These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has multiple opportunities to engage with and understand these important results,” said Ben Zeskind, Ph.D., CEO of Immuneering. Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 9502940. A webcast replay will be available from the “Investors” section of the Company’s website here. The Immuneering September 2025 corporate presentation can be found here and the September 24, 2025 press release announcing updated overall survival and safety data in first-line pancreatic cancer patients can be found here. About ImmuneeringImmuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.  Media Contact:Carson Creehan817-412-1096carson.creehan@padillaco.com Investor Contact:Laurence Watts619-916-7620laurence@newstreetir.com

Related News